These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 10463486)

  • 1. Evaluation of HER-2/neu (erbB-2) status in breast cancer: from bench to bedside.
    Hanna W; Kahn HJ; Trudeau M
    Mod Pathol; 1999 Aug; 12(8):827-34. PubMed ID: 10463486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted therapy for cancer: the HER-2/neu and Herceptin story.
    Ross JS; Gray GS
    Clin Leadersh Manag Rev; 2003; 17(6):333-40. PubMed ID: 14692077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trastuzumab: targeted therapy for the management of HER-2/neu-overexpressing metastatic breast cancer.
    Emens LA
    Am J Ther; 2005; 12(3):243-53. PubMed ID: 15891269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HER-2/neu expression in primary and metastatic breast cancer.
    Lower EE; Glass E; Blau R; Harman S
    Breast Cancer Res Treat; 2009 Jan; 113(2):301-6. PubMed ID: 18273700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HER-2/neu status of primary breast cancer and corresponding metastatic sites in patients with advanced breast cancer treated with trastuzumab-based therapy.
    Pectasides D; Gaglia A; Arapantoni-Dadioti P; Bobota A; Valavanis C; Kostopoulou V; Mylonakis N; Karabelis A; Pectasides M; Economopoulos T
    Anticancer Res; 2006; 26(1B):647-53. PubMed ID: 16739334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy.
    Ross JS; Fletcher JA
    Stem Cells; 1998; 16(6):413-28. PubMed ID: 9831867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hidden HER-2/neu-positive breast cancer: how to maximize detection.
    Carney WP
    IDrugs; 2009 Apr; 12(4):238-42. PubMed ID: 19350468
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant therapy with trastuzumab for HER-2/neu-positive breast cancer.
    Gonzalez-Angulo AM; Hortobágyi GN; Esteva FJ
    Oncologist; 2006 Sep; 11(8):857-67. PubMed ID: 16951389
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HER2/neu role in breast cancer: from a prognostic foe to a predictive friend.
    Ferretti G; Felici A; Papaldo P; Fabi A; Cognetti F
    Curr Opin Obstet Gynecol; 2007 Feb; 19(1):56-62. PubMed ID: 17218853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting fatty acid synthase-driven lipid rafts: a novel strategy to overcome trastuzumab resistance in breast cancer cells.
    Menendez JA; Vellon L; Lupu R
    Med Hypotheses; 2005; 64(5):997-1001. PubMed ID: 15780499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HER-2/neu gene product in serum--an oncoprotein in the diagnosis and therapy of breast carcinoma.
    Schulze G
    Anticancer Res; 2003; 23(2A):1007-10. PubMed ID: 12820339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [HER-2 diagnostics].
    Bánkfalvi A
    Magy Onkol; 2002; 46(1):11-5. PubMed ID: 12050677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effect of Herceptin combined with Taxol on patients with Her-2/neu overexpressing metastatic breast cancer].
    Luo RC; Li AM; Zhang JY; Liao WJ; Ji CY; Miao JX
    Zhonghua Zhong Liu Za Zhi; 2004 Jan; 26(1):52-4. PubMed ID: 15059359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting Her-2/neu in breast cancer: as easy as this!
    Azim H; Azim HA
    Oncology; 2008; 74(3-4):150-7. PubMed ID: 18708732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HER-2/neu assessment in breast cancer using the original FDA and new ASCO/CAP guideline recommendations: impact on selecting patients for herceptin therapy.
    Brunelli M; Manfrin E; Martignoni G; Bersani S; Remo A; Reghellin D; Chilosi M; Bonetti F
    Am J Clin Pathol; 2008 Jun; 129(6):907-11. PubMed ID: 18480007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Accurately assessing her-2/neu status in needle core biopsies of breast cancer patients in the era of neoadjuvant therapy: emerging questions and considerations addressed.
    D'Alfonso T; Liu YF; Monni S; Rosen PP; Shin SJ
    Am J Surg Pathol; 2010 Apr; 34(4):575-81. PubMed ID: 20216378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [HER-2/neu oncogene in the selection of treatment for breast cancer and as a target of immunotherapy].
    Isola J; Järvinen T; Tanner M; Holli K
    Duodecim; 2000; 116(15):1538-46. PubMed ID: 12001473
    [No Abstract]   [Full Text] [Related]  

  • 18. Prognostic and predictive value of HER2/neu oncogene in breast cancer.
    Masood S; Bui MM
    Microsc Res Tech; 2002 Oct; 59(2):102-8. PubMed ID: 12373720
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum EGFR levels and efficacy of trastuzumab-based therapy in patients with metastatic breast cancer.
    Hudelist G; Köstler WJ; Gschwantler-Kaulich D; Czerwenka K; Kubista E; Müller R; Helmy S; Manavi M; Zielinski CC; Singer CF
    Eur J Cancer; 2006 Jan; 42(2):186-92. PubMed ID: 16326100
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
    Diermeier S; Horváth G; Knuechel-Clarke R; Hofstaedter F; Szöllosi J; Brockhoff G
    Exp Cell Res; 2005 Apr; 304(2):604-19. PubMed ID: 15748904
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.